ArticleCanadian journal of gastroenterology & hepatology2025
Tumor Budding and E-Cadherin Loss as Robust Prognostic Markers in Pancreatic Ductal Adenocarcinoma: A Study in a Turkish Patient Cohort.
Article in Canadian journal of gastroenterology & hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Digital Pathology and the AI-Based Quantification of the Tumor Microenvironment in Gastrointestinal Cancer: From Tumor Budding and Tumor-Infiltrating Lymphocytes to Tertiary Lymphoid Structures.International journal of molecular sciences · 2026Review
- Review
- Comprehensive Overview of Gastric Cancer Immunohistochemistry: Key Biomarkers, Advanced Detection Methods, and Perspectives.Medicina (Kaunas, Lithuania) · 2026Review
- From biology to morphology and treatment: the current role of pathology in penile cancer - a narrative review.Frontiers in oncology · 2026Review
- Tumor Budding and E-Cadherin Loss as Robust Prognostic Markers in Pancreatic Ductal Adenocarcinoma: A Study in a Turkish Patient Cohort.Canadian journal of gastroenterology & hepatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study investigates the prognostic significance of tumor budding and its association with E-cadherin expression in pancreatic ductal adenocarcinoma (PDAC) with a focus on a Turkish patient cohort. Methods: A total of 76 patients who had undergone resection of PDAC were analyzed. Tumor budding was assessed according to Tumor Budding Consensus Conference (ITBCC) guideline and classified as low (1-4 buds), medium (5-9 buds), or high (≥ 10 buds). E-cadherin expression was assessed by immunohistochemistry and categorized as low, moderate, or high. The correlations between tumor budding, clinicopathological factors, and survival were statistically analyzed and examined, and Results: Tumor budding was detected in 42.1% of patients, significantly associated with advanced tumor stage ( Conclusions: Tumor budding is a reliable prognostic marker in PDAC, demonstrating significant associations with poor clinical outcomes, including advanced tumor stage and reduced survival. These findings support the integration of tumor budding into clinical guidelines to enhance prognostic precision and guide treatment decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.